Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
2(50.0%)
Phase 2
2(50.0%)
4Total
Phase 1(2)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT02989636Phase 1Active Not Recruiting

Nivolumab With or Without Stereotactic Radiosurgery in Treating Patients With Recurrent, Advanced, or Metastatic Chordoma

Role: collaborator

NCT03083678Phase 2Completed

Afatinib in Locally Advanced and Metastatic Chordoma

Role: collaborator

NCT06794645Phase 2Recruiting

Pembrolizumab and Pemetrexed for Progressive Chordoma

Role: collaborator

NCT03955042Phase 1Completed

Pemetrexed for the Treatment of Chordoma

Role: collaborator

All 4 trials loaded